MedTrace Logo

SARS-CoV-2 and Herpesvirus Inhibition for Ending Long COVID Dysfunction

NCT07597902 · Status: NOT_YET_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 150

Last updated 2026-05-19

No results posted yet for this study

Summary

The purpose of this research study is to test if the combination of three drugs, valacyclovir, celecoxib, and Paxlovid will decrease the symptoms of Long COVID in adults compared to a placebo (this does not contain the medications).

Conditions

Interventions

DRUG

Placebo

matching placebo capsules and tablets taken orally in the morning and evening

DRUG

Valacyclovir

one to two 750mg capsules taken orally in the morning and evening

DRUG

Celecoxib

200mg capsules taken orally in the morning and evening

DRUG

Paxlovid

one (100mg ritonavir tablet and two 150mg nirmatrelvir tablets) taken orally in the morning and evening

Sponsors & Collaborators

Principal Investigators

  • David Putrino, PhD · Icahn School of Medicine at Mount Sinai

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-06-01
Primary Completion
2028-06-30
Completion
2028-06-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07597902 on ClinicalTrials.gov